Equities Analysts Issue Forecasts for BrainsWay Q1 Earnings

BrainsWay Ltd. (NASDAQ:BWAY) – Investment analysts at HC Wainwright decreased their Q1 2025 earnings estimates for BrainsWay in a report issued on Wednesday, March 12th. HC Wainwright analyst R. Selvaraju now expects that the company will earn $0.03 per share for the quarter, down from their prior estimate of $0.06. HC Wainwright currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for BrainsWay’s Q2 2025 earnings at $0.04 EPS, Q3 2025 earnings at $0.05 EPS, Q4 2025 earnings at $0.06 EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.07 EPS, Q4 2026 earnings at $0.08 EPS and FY2026 earnings at $0.24 EPS.

BrainsWay Stock Performance

BWAY stock opened at $10.21 on Friday. The company’s 50 day moving average price is $10.26 and its 200 day moving average price is $9.61. BrainsWay has a fifty-two week low of $4.61 and a fifty-two week high of $11.79. The firm has a market capitalization of $192.22 million, a price-to-earnings ratio of 102.11 and a beta of 1.29.

Institutional Trading of BrainsWay

A number of large investors have recently made changes to their positions in the company. Two Sigma Investments LP increased its stake in shares of BrainsWay by 2.0% during the fourth quarter. Two Sigma Investments LP now owns 92,755 shares of the company’s stock worth $875,000 after buying an additional 1,786 shares during the period. Rhumbline Advisers boosted its holdings in BrainsWay by 10.8% in the fourth quarter. Rhumbline Advisers now owns 21,966 shares of the company’s stock valued at $207,000 after purchasing an additional 2,144 shares in the last quarter. Cubist Systematic Strategies LLC boosted its holdings in BrainsWay by 14.6% in the fourth quarter. Cubist Systematic Strategies LLC now owns 19,228 shares of the company’s stock valued at $181,000 after purchasing an additional 2,446 shares in the last quarter. Lazard Asset Management LLC acquired a new position in BrainsWay in the fourth quarter valued at approximately $44,000. Finally, JPMorgan Chase & Co. boosted its holdings in BrainsWay by 61.9% in the fourth quarter. JPMorgan Chase & Co. now owns 23,918 shares of the company’s stock valued at $226,000 after purchasing an additional 9,149 shares in the last quarter. 30.11% of the stock is currently owned by hedge funds and other institutional investors.

BrainsWay Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.